Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Progression02:07

Tumor Progression

6.5K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.5K
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

3.3K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Continuous or Fixed-Duration Maintenance Therapy in Multiple Myeloma.

The New England journal of medicine·2026
Same author

Effectiveness of daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) versus VRd for transplant-eligible newly diagnosed multiple myeloma.

Future oncology (London, England)·2026
Same author

Concurrent administration of BCMA and GPRC5D chimeric antigen receptor (CAR) T cells in advanced multiple myeloma.

Blood·2026
Same author

Author Correction: Teclistamab-based induction treatment in transplant-eligible, newly diagnosed multiple myeloma: a phase 2 trial.

Nature medicine·2026
Same author

Clinical decision support in hematological malignancies using a case-grounded AI agent.

Nature medicine·2026
Same author

Clinical Course, Risk Factors, and Therapeutic Response in Multiple Myeloma with Central Nervous System Involvement.

Blood advances·2026

Related Experiment Video

Updated: Sep 10, 2025

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma
15:07

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma

Published on: December 28, 2015

26.8K

Temporal genomic dynamics shape clinical trajectory in multiple myeloma.

Francesco Maura1,2, Marcella Kaddoura3, Alexandra M Poos4,5

  • 1Myeloma Institute, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, USA. mauraf@mskcc.org.

Nature Genetics
|August 20, 2025
PubMed
Summary

Multiple myeloma develops over decades, with chromosomal gains like 1q gain impacting outcomes based on when they occur, not just how many copies are present.

More Related Videos

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

21.5K
Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies
06:33

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies

Published on: November 10, 2023

1.3K

Related Experiment Videos

Last Updated: Sep 10, 2025

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma
15:07

VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma

Published on: December 28, 2015

26.8K
Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

21.5K
Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies
06:33

Author Spotlight: Analyzing Bone Marrow Microenvironment in Murine Hematological Malignancies

Published on: November 10, 2023

1.3K

Area of Science:

  • Genomics
  • Cancer Biology
  • Hematology

Background:

  • Multiple myeloma (MM) is a plasma cell malignancy.
  • MM evolution involves accumulating genomic alterations.
  • Understanding the timeline of these alterations is crucial for prognosis.

Purpose of the Study:

  • To determine the timeline of genomic driver acquisition in multiple myeloma.
  • To investigate the impact of the timing of specific genetic events on clinical outcomes.

Main Methods:

  • Whole-genome sequencing of 421 samples from 382 multiple myeloma patients.
  • Analysis of mutational signatures to estimate event timing.
  • Correlation of genomic event timing with patient survival data.

Main Results:

  • A significant time lag of 20-40 years exists between initial genomic events and MM diagnosis.
  • Odd-numbered chromosome trisomies can arise concurrently with other gains, such as 1q gain.
  • Hyperdiploidy acquisition occurs after immunoglobulin heavy chain translocations when co-occurring.
  • Early 1q gain is associated with adverse outcomes, comparable to 1q amplification, and worse than late 1q gain.

Conclusions:

  • The timing of genomic alterations, particularly 1q gain, is a critical determinant of clinical outcome in multiple myeloma.
  • This study provides insights into the evolutionary history of multiple myeloma.
  • Findings may inform prognostic stratification and therapeutic strategies for multiple myeloma patients.